南京医药集团股份有限公司关于公司及子公司使用部分暂时闲置募集资金进行现金管理到期赎回的公告

Group 1 - The company approved the use of up to 700 million yuan of temporarily idle raised funds for cash management, investing in low-risk, high-liquidity principal-protected financial products [1] - The cash management initiative is valid for 12 months from the date of board approval, with the option for rolling use and repayment to the dedicated fundraising account upon maturity [1] - On October 9, 2025, the subsidiary Fujian Tongchun Pharmaceutical Co., Ltd. purchased a large time deposit of 60 million yuan from China Merchants Bank, which matured on January 9, 2026, yielding a return of 165,000 yuan [2] Group 2 - The principal and earnings from the time deposit have been returned to the dedicated fundraising account, meeting the expected financial returns [2] - The company has been actively managing its raised funds over the past twelve months, indicating a strategic approach to financial management [2]